[{"id":"5cbe18a7-53bc-4741-8463-14864cc423d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013423","created_at":"2023-08-28T14:08:26.842Z","updated_at":"2024-07-02T16:34:37.149Z","phase":"Phase 2","brief_title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","source_id_and_acronym":"NCT06013423","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/06/2024","start_date":" 07/06/2024","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-06-07"},{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2024-07-02T16:34:37.908Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • revumenib (SNDX-5613) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-05"},{"id":"cb2c4839-09e4-41a3-9033-1bd13594665c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01860937","created_at":"2021-01-18T08:19:12.565Z","updated_at":"2024-07-02T16:34:38.169Z","phase":"Phase 1","brief_title":"T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01860937","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • IKZF1 deletion","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • IKZF1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2024-07-02T16:34:59.983Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • ziftomenib (KO-539) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-30"},{"id":"64862772-4e2d-4d09-a25e-0a3cd662c549","acronym":"AALL1621","url":"https://clinicaltrials.gov/study/NCT02981628","created_at":"2021-01-18T14:40:03.526Z","updated_at":"2024-07-02T16:35:00.110Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02981628 - AALL1621","lead_sponsor":"Children's Oncology Group","biomarkers":" KMT2A • CD22","pipe":" | ","alterations":" MLL rearrangement • CD22 expression","tags":["KMT2A • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/19/2017","start_date":" 06/19/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-30"},{"id":"309336fe-c633-4941-857b-be9dfdd1dccf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114865","created_at":"2021-01-18T15:20:34.297Z","updated_at":"2024-07-02T16:35:00.894Z","phase":"Phase 1/2","brief_title":"A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance","source_id_and_acronym":"NCT03114865","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-27"},{"id":"34e695f6-dbe3-425d-b9ce-de960e381284","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644016","created_at":"2021-01-19T20:39:14.570Z","updated_at":"2024-07-02T16:35:01.196Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","source_id_and_acronym":"NCT04644016","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-05-24"},{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2024-07-02T16:35:00.956Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-24"},{"id":"f8c1fb30-1e93-4d1d-b601-a40aa00e7c6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01995578","created_at":"2021-01-18T09:06:13.620Z","updated_at":"2024-07-02T16:35:02.011Z","phase":"Phase 2","brief_title":"Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse","source_id_and_acronym":"NCT01995578","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 09/27/2023","primary_completion_date":" 09/27/2023","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2024-05-22"},{"id":"66017a7e-e1f3-43a3-a59a-3c773b2ee231","acronym":"AUGMENT-101","url":"https://clinicaltrials.gov/study/NCT04065399","created_at":"2021-01-18T19:55:07.775Z","updated_at":"2024-07-02T16:35:03.156Z","phase":"Phase 1/2","brief_title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04065399 - AUGMENT-101","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" KMT2A • NUP98","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement","tags":["KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e revumenib (SNDX-5613) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 413","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-17"},{"id":"effe32d4-632d-47ed-9569-8f5ee71685a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326516","created_at":"2022-04-13T11:55:14.906Z","updated_at":"2024-07-02T16:35:02.858Z","phase":"Phase 1","brief_title":"A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia","source_id_and_acronym":"NCT05326516","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" KMT2A • NUP98","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • revumenib (SNDX-5613)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/09/2022","start_date":" 03/09/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-17"},{"id":"c62a7f73-b1c2-406a-b3bd-f74ccdc4bd18","acronym":"KOMET-007","url":"https://clinicaltrials.gov/study/NCT05735184","created_at":"2023-02-21T16:01:44.880Z","updated_at":"2024-07-02T16:35:03.357Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML","source_id_and_acronym":"NCT05735184 - KOMET-007","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • daunorubicin • ziftomenib (KO-539)"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-16"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"9f272c5e-b3bc-4746-bc47-098aa2fc3e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05884333","created_at":"2023-06-01T14:08:00.739Z","updated_at":"2024-07-02T16:35:06.471Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Adults With Blood Cancers","source_id_and_acronym":"NCT05884333","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 05/22/2028","primary_completion_date":" 05/22/2028","study_txt":" Completion: 05/22/2028","study_completion_date":" 05/22/2028","last_update_posted":"2024-05-02"},{"id":"77accf55-b1ad-4e14-aada-f3a5e55d16c9","acronym":"EU PIP Study","url":"https://clinicaltrials.gov/study/NCT05748171","created_at":"2023-02-28T13:01:32.364Z","updated_at":"2024-07-02T16:35:06.949Z","phase":"Phase 2","brief_title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to ","source_id_and_acronym":"NCT05748171 - EU PIP Study","lead_sponsor":"Pfizer","biomarkers":" TP53 • KMT2A • CD22 • TCF3 • PBX1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD22 positive","tags":["TP53 • KMT2A • CD22 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 07/11/2028","primary_completion_date":" 07/11/2028","study_txt":" Completion: 07/09/2031","study_completion_date":" 07/09/2031","last_update_posted":"2024-04-30"},{"id":"52201742-0575-4575-a34b-9248823aad77","acronym":"APAL2020SC","url":"https://clinicaltrials.gov/study/NCT04726241","created_at":"2021-01-27T13:53:55.563Z","updated_at":"2024-07-02T16:35:08.447Z","phase":"Phase 1/2","brief_title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia \u0026 Lymphoma Society and Children's Oncology Group Study","source_id_and_acronym":"NCT04726241 - APAL2020SC","lead_sponsor":"LLS PedAL Initiative, LLC","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 960","initiation":"Initiation: 04/18/2022","start_date":" 04/18/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-22"},{"id":"96dc9fc0-af06-4f1e-b4e5-802d917774dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05761171","created_at":"2023-03-09T15:01:28.014Z","updated_at":"2024-07-02T16:35:08.400Z","phase":"Phase 2","brief_title":"A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","source_id_and_acronym":"NCT05761171","lead_sponsor":"Children's Oncology Group","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • vincristine • revumenib (SNDX-5613) • Oncaspar liquid (pegaspargase) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 01/08/2024","start_date":" 01/08/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-04-22"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2024-07-02T16:35:09.543Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 01/10/2025","primary_completion_date":" 01/10/2025","study_txt":" Completion: 11/10/2025","study_completion_date":" 11/10/2025","last_update_posted":"2024-04-16"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"7c4b8485-206a-4268-adbf-1fdeb567ca5c","acronym":"Interfant-21","url":"https://clinicaltrials.gov/study/NCT05327894","created_at":"2022-04-14T11:53:34.155Z","updated_at":"2024-07-02T16:35:11.206Z","phase":"Phase 3","brief_title":"Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia","source_id_and_acronym":"NCT05327894 - Interfant-21","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-04-05"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2024-07-02T16:35:11.899Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • IKZF1 deletion • ABL1 fusion • ABL1 deletion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • IKZF1 deletion • ABL1 fusion • ABL1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2027","study_completion_date":" 04/02/2027","last_update_posted":"2024-04-02"},{"id":"6227118e-f47f-4c7a-b5cc-7353c6ece1aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01684150","created_at":"2021-01-18T07:18:03.871Z","updated_at":"2024-07-02T16:35:12.815Z","phase":"Phase 1","brief_title":"A Phase 1, Open-Label, Dose-Escalation \u0026 Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK \u0026 PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving","source_id_and_acronym":"NCT01684150","lead_sponsor":"Epizyme, Inc.","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pinometostat (EPZ-5676)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2024-03-26"}]